WO2017023138A1 - 키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포 - Google Patents
키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포 Download PDFInfo
- Publication number
- WO2017023138A1 WO2017023138A1 PCT/KR2016/008632 KR2016008632W WO2017023138A1 WO 2017023138 A1 WO2017023138 A1 WO 2017023138A1 KR 2016008632 W KR2016008632 W KR 2016008632W WO 2017023138 A1 WO2017023138 A1 WO 2017023138A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- domain
- antigen receptor
- seq
- chimeric antigen
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 72
- 210000001744 T-lymphocyte Anatomy 0.000 title description 67
- 239000000427 antigen Substances 0.000 claims abstract description 83
- 102000036639 antigens Human genes 0.000 claims abstract description 83
- 108091007433 antigens Proteins 0.000 claims abstract description 83
- 230000027455 binding Effects 0.000 claims abstract description 60
- 230000001086 cytosolic effect Effects 0.000 claims abstract description 21
- 230000011664 signaling Effects 0.000 claims abstract description 13
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims description 50
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims description 50
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 46
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 43
- 150000001413 amino acids Chemical group 0.000 claims description 29
- 235000001014 amino acid Nutrition 0.000 claims description 22
- 229940024606 amino acid Drugs 0.000 claims description 19
- 230000000638 stimulation Effects 0.000 claims description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 15
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 15
- 230000004936 stimulating effect Effects 0.000 claims description 11
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 10
- 239000004471 Glycine Substances 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- 230000033115 angiogenesis Effects 0.000 claims description 7
- 102000010956 Glypican Human genes 0.000 claims description 5
- 108050001154 Glypican Proteins 0.000 claims description 5
- 108050007238 Glypican-1 Proteins 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 3
- -1 αVβ3 Proteins 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 230000002491 angiogenic effect Effects 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 2
- 108010083359 Antigen Receptors Proteins 0.000 claims 2
- 102000006306 Antigen Receptors Human genes 0.000 claims 2
- 108010055196 EphA2 Receptor Proteins 0.000 claims 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 172
- 206010028980 Neoplasm Diseases 0.000 description 75
- 108090000176 Interleukin-13 Proteins 0.000 description 51
- 102000003816 Interleukin-13 Human genes 0.000 description 51
- 108090000623 proteins and genes Proteins 0.000 description 49
- 201000011510 cancer Diseases 0.000 description 47
- 102200024855 rs886037778 Human genes 0.000 description 39
- 230000014509 gene expression Effects 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 33
- 102220474088 Protection of telomeres protein 1_S67D_mutation Human genes 0.000 description 31
- 208000005017 glioblastoma Diseases 0.000 description 20
- 231100000135 cytotoxicity Toxicity 0.000 description 19
- 230000003013 cytotoxicity Effects 0.000 description 19
- 102100037850 Interferon gamma Human genes 0.000 description 17
- 108010074328 Interferon-gamma Proteins 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 17
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 13
- 229960004964 temozolomide Drugs 0.000 description 13
- 238000011580 nude mouse model Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 238000000684 flow cytometry Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 9
- 241000699660 Mus musculus Species 0.000 description 9
- 239000012636 effector Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 208000003174 Brain Neoplasms Diseases 0.000 description 7
- 230000001093 anti-cancer Effects 0.000 description 7
- 238000010361 transduction Methods 0.000 description 7
- 230000026683 transduction Effects 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 150000002333 glycines Chemical class 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 238000010586 diagram Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 4
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 description 4
- 101710112663 Interleukin-13 receptor subunit alpha-1 Proteins 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001772 anti-angiogenic effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 102100034190 Glypican-1 Human genes 0.000 description 3
- 101001070736 Homo sapiens Glypican-1 Proteins 0.000 description 3
- 101100286681 Homo sapiens IL13 gene Proteins 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 102000050327 human TNFRSF9 Human genes 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 101710160107 Outer membrane protein A Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 101150058049 car gene Proteins 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 239000010751 BS 2869 Class A2 Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007727 Muscle Tissue Neoplasms Diseases 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 208000021592 benign granular cell tumor Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000004130 myoblastoma Diseases 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 108010078373 tisagenlecleucel Proteins 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464419—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464422—Ephrin Receptors [Eph]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464474—Proteoglycans, e.g. glypican, brevican or CSPG4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/22—Intracellular domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the present invention relates to chimeric antigen receptors that recognize cancer cell surface antigens and T cells in which they are expressed. Specifically, the present invention relates to chimeric antigen receptors having excellent expression rate and T cells in which they are expressed. More specifically, the present invention provides a cancer cell surface antigen binding domain; Hinge region; Transmembrane domain; A chimeric antigen receptor comprising a costimulatory domain and a cytoplasmic signaling domain, wherein the costimulatory domain consists of mutated CD28 or TNFRSF9 and relates to a chimeric antigen receptor and a T cell expressing it. will be.
- the present invention the chimeric antigen receptor and T cells expressed therein, wherein the antigen binding domain binds to an antigen selected from the group consisting of IL13R ⁇ 2, antigens related to angiogenesis, EGFRvlll, EphA2, ⁇ V ⁇ 3, and glypican1. It relates to a chimeric antigen receptor and a T cell in which it is expressed.
- the present invention relates to a chimeric antigen receptor and a T cell expressed therein, wherein in the chimeric antigen receptor and a T cell expressed therein, three glycines are additionally introduced between the antigen binding domain and the hinge region. will be.
- the present invention is directed to the chimeric antigen receptor and the T cells in which the cytoplasmic signal domains of normal humans containing additional glutamine (extra Glutamine), which are not CD3 ⁇ signaling domains of Jurkat T cells.
- a chimeric antigen receptor characterized by the use of the CD3 ⁇ signaling domain and a T cell in which it is expressed.
- the present invention relates to chimeric antigen receptors and T cells in which they are expressed, including or all of the predetermined antigen binding domains, auxiliary stimulatory domains and cytoplasmic signal domains disclosed above.
- CAR-T cells T cells expressing chimeric antigen receptors (hereinafter sometimes referred to as “CAR” in the present specification) may be specifically referred to as “CAR-T cells” in the present specification) on the surface of cancer cells. It refers to a T cell in which the gene is recombined to introduce a gene encoding a receptor that recognizes a cancer cell surface antigen to be expressed into T cells to kill cancer cells. Dr. Chemist and Immunologist at the Weizmann Institute of Science in Israel Zelig Eshhar et al.
- T cells equipped with chimeric antigen receptors He succeeded in creating a new model and published it in PNAS in 1989.
- CAR-T cells produced in the early days that is, first generation CAR-T cells using only CD3 ⁇ as a signal transduction domain
- the therapeutic effect was insignificant, and also had a short duration.
- Efforts have been made to improve the reactivity of CAR-T cells, and second generation CAR-T cells combining CD3 ⁇ with an adjuvant stimulating domain (CD28 or CD137 / 4-1BB) have been prepared compared to first generation CAR-T cells. This significantly increased the number of CAR-T cells remaining in the body.
- second generation CAR-T cells used one adjuvant stimulation domain.
- CAR-T cells using two adjuvant stimulation domains are referred to as 3rd generation CAR-T, and the current study is a 2nd and 3rd generation CAR. It is concentrated in T cells.
- cytotoxic T cells modified to recognize CD19 in three patients with chronic lymphoid leukemia (CCL) Two of them reported complete remission of leukemia, and the condition persisted for about 10 months (N. Engl J Med 2011; 365: 725-733 August 25, 2011, Sic. Transl.
- the CAR-T used here corresponds to the second generation, using 4-1BB as the auxiliary stimulation domain and CD3 ⁇ as the signal transduction domain.
- the antigen binding domain of the CAR-T cells recognizes CD19 as an antigen found on the surface of leukemia cancer cells.
- CAR-T cancer treatment using CAR-T cells is a self-derived method and not a mass-produced product, but as the patient is customized, the therapeutic effect is incomparable with conventional anticancer drugs.
- the present invention is to provide a CAR and CAR-T cells with a markedly superior expression rate and therapeutic effect compared to CAR-T cells known in the art.
- it is a problem to provide an auxiliary stimulation domain that can be introduced into various CAR-T cells as an auxiliary stimulation domain that plays a major role in its function in second and third generation CAR-T cells.
- it is a problem to provide various antigen binding domains that can bind to antigens expressed on the surface of specific cancer cells and are capable of forming CAR-T cells.
- a chimeric antigen receptor characterized by having an additional amino acid sequence that can be additionally introduced between the antigen binding domain and the hinge region in various CAR-T cells
- a method of improving the expression rate of CAR-T cells and its therapeutic effect It is technical problem to provide.
- Antigen binding domains Hinge area; Transmembrane domain; Secondary stimulation domain; And a chimeric antigen receptor comprising a cytoplasmic signal domain, wherein the chimeric antigen receptor independently comprises a specific auxiliary stimulation domain, or a specific amino acid sequence added between a specific antigen binding domain, an antigen binding domain and a hinge region, or wherein the cytoplasmic signal domain is Jurkat T
- a chimeric antigen receptor characterized by, or in combination with, the use of a CD3 ⁇ signaling domain in a normal person with additional extra glutamine, but not the CD3 ⁇ signaling domain of the cell, and which expression Initiated CAR-T cells.
- An antigen binding domain disclosed in the present invention Or an auxiliary stimulation domain; Or CAR-T cells comprising a signal transduction domain has the effect of remarkably excellent therapeutic efficacy and expression rate.
- Figure 1 shows retroviral vectors and transplant genes showing the major functional elements of one embodiment of CAR-T cells disclosed herein. Specifically mutated IL13 (E11K.R64D.S67D.R107K), human CD8 ⁇ hinge and human CD8 / human CD3 transmembrane domain, to give higher antigen affinity than the two amino acid substitutions of IL13 (Glu-11, Arg-107), Clinical grade retroviral vectors that direct expression of mutant human CD28 (RLLH ⁇ RGG), human TNFRSF9, and CD3 zeta signaling domains in healthy humans are shown to increase CAR expression rate. The figures are not drawn to scale.
- FIG. 2 is a diagram showing that the expression rate is increased after the addition of three glycine between the antigen binding domain and the hinge site in order to increase the solubility of the CAR protein to increase the expression of the chimeric antigen receptor.
- Figure 3 shows that the expression rate increases when using a mutation of human CD28 (RLLH ⁇ RGGH) to increase the expression of chimeric antigen receptor of CAR protein.
- FIG. 4 is a diagram showing the results of analyzing the T-cells transformed to confirm the CAR-T cell purity and CAR expression rate produced by the manufacturing process set up for clinical use using a flow cytometry analysis. It is a figure which shows cell purity.
- FIG. 5 shows cytotoxicity of T-cells into which two positions are substituted IL13 (Glu-11, Arg-107) and four positions are substituted IL13 (IL13.E11K.R64D.S67D.R107K). Is a diagram comparing.
- FIG. 6 is a diagram showing increased expression rate of anticancer activity in human brain cancer cell line U251 of CAR-T cells consisting of four positions substituted IL13 (E11K.R64D.S67D.R107K) .TNFRSF9.CD3 ⁇ .
- IL13R ⁇ 2 overexpression is a human brain cancer cell line U251 (IL13R ⁇ 2 overexpression) which is a CAR-T cell consisting of IL13 (E11K.R64D.S67D.R107K) TNFRSF9.CD3 ⁇ substituted with four positions and HUVEC (IL13R ⁇ 2 expression) which is a normal cell control. Lack) IFN- ⁇ cytokine production after 19 hours incubation at 0.5: 1 ratio.
- FIG. 8 shows IFN- ⁇ cytokine production after 19 hours of incubation of a human brain cancer cell line U251, which is a target cell with CAR-T cells containing four positions (IL13.E11K.R64D.S67D.R107K) .TNFRSF9.CD3 ⁇ . It is a figure which shows the increase of anti-cancer activity dependent on CAR-T cell number dependence.
- FIG. 9A is a schematic image showing a method of testing nude mice in vivo using CAR-T cells including IL13 (E11K.R64D.S67D.R107K) TNFRSF9.CD3 ⁇ substituted with four positions
- FIG. 9B is a diagram showing the CAR. The figure which shows the result of measuring tumor size of an animal 12 days after -T cell or PBS treatment.
- FIG. 9C shows the shape, size, and weight of cancer tissue removed from nude mice 15 days after the CAR-T cells or PBS treatment.
- FIG. 10A shows anti-human CD3 antibody of cancer tissue removed from nude mice 15 days after TMZ + PBS (PBS was administered once intravenously, TMZ and IL-2 were administered once daily for 4 days once intraperitoneally and intravenously). It is an image stained with T cells.
- FIG. 10B shows that CAR-T cells containing TMZ + YYB103 (TMZ and four positions substituted IL13 (E11K.R64D.S67D.R107K) TNFRSF9.CD3 ⁇ were administered intravenously once, with TMZ and IL-2 intraperitoneally, respectively. And intravenous four days a day) 15 days later cancer tissues removed from nude mice were stained with T cells using anti-human CD3 antibody.
- FIG. 11A shows H & E staining of cancer tissue removed from nude mice 15 days after TMZ + PBS (PBS was administered once intravenously, TMZ and IL-2 were administered once daily for 4 days once intraperitoneally and intravenously). .
- FIG. 11B shows that CAR-T cells containing TMZ + YYB103 (TMZ and four positions substituted IL13 (E11K.R64D.S67D.R107K) TNFRSF9.CD3 ⁇ were administered intravenously once, with TMZ and IL-2 intraperitoneally, respectively. And intravenous 4 days once daily) H & E staining of cancer tissue removed from nude mice 15 days later.
- FIG. 12 shows that successful anticancer CAR therapy requires an immunosupportive environment for maintaining CAR-T cell function and access of CAR-T cells to cancer cells as well as antigen specific CAR-T cells.
- FIG. 12A shows an Anti-Angiogenic CAR transplant gene representing major functional elements
- FIG. 12B shows a flow cytometry analysis of cells transformed with the gene constructs for expression on the cell surface of the Anti-Angiogenic CAR. It is a figure which shows the result of using and analyzing.
- FIGS. 13-16 show CAR construction targeting the major tumor antigens of various cancers.
- a of each figure represents a CAR transplant gene representing a major functional element
- B of each figure using a flow cytometry analysis of the cells transformed using the gene constructs for expression on the cell surface of the CAR It is a figure which shows the result of an analysis.
- CAR-T cells is a genetically recombined T cells incorporating a receptor gene that recognizes cancer cells as antigens, comprising: an antigen binding domain that recognizes an antigen; A hinge region (or spacer) connecting the antigen binding domain and the transmembrane domain; Transmembrane domain; Secondary stimulation domain; And cytoplasmic signal domains.
- the antigen binding domain is a site where the main signal is transmitted and is outside the cell membrane and recognizes cancer cells expressing specific antigens.
- the specific therapeutic target is determined by the antigen binding domain, but the present invention does not limit such antigen binding domain to a specific one, but is overexpressed, for example, in the myoblastoma.
- a chimeric antigen receptor capable of specifically binding to IL13R ⁇ 2 is disclosed.
- Glioblastoma (GBM) or glioblastoma multiforme is one of the most common brain tumors, accounting for about 12-15% of brain tumors, and is a common malignant brain cancer.
- Glioblastoma cells are similar to astrocytes, which maintain and nourish nerve cells and are responsible for the protective response to damage to brain tissue. Genetic abnormalities of stem cells or immature stellate cells are thought to be involved in the development and malignancy of glioblastoma.
- surgery radiation therapy and chemotherapy are used.
- chemotherapy agents temozolomide, romustine, carmustine, and the like are used, and clinical trials such as tumor vaccine treatment and molecular target treatment have recently been conducted.
- there is still no useful therapeutic agent for the treatment of glioblastoma there is still no useful therapeutic agent for the treatment of glioblastoma.
- the sequence of the antigen-binding domain that binds IL13R ⁇ 2 is shown in SEQ ID NO: 1, in particular, the mutant IL13 in which positions 11, 64, 67, and 107 are replaced with E11K.R64D.S67D.R107K, respectively, is newly manufactured. Is initiated. It should be noted, however, that amino acids substituted at the corresponding positions may be replaced with amino acids having properties similar to those specified above. Thus, at 11, instead of lysine (K), arginine (R) or histidine (H); At 64 and 67 with glutamic acid (E) instead of aspartic acid (D); At 107 it can be replaced by histidine (H) instead of lysine (K).
- IL13 (E11K.R64D.S67D.R107K) in which the four positions disclosed in the present invention are mutated and analogs substituted with amino acids of the same nature at the same position have increased antigen affinity.
- the antigen binding domain of the present invention can be produced to bind to antigens expressed on various cancer cells as well as IL13R ⁇ 2 overexpressed in glioblastoma cells.
- an antigen binding domain SEQ ID NO: 2 capable of binding with an antigen associated with angiogenesis
- Antigen binding domains SEQ ID NO: 3 that bind EGFRvlll, a major tumor antigen such as glioblastoma and lung cancer
- An antigen binding domain (SEQ ID NO: 4) that binds to EphA2, a tumor antigen such as glioblastoma, breast cancer, or prostate cancer
- Antigen-binding domains that bind to ⁇ V ⁇ 3, a resistant marker of tyrosine kinases (RTKIs) such as carcinoma stemness and erlotinib in pancreatic cancer, lung cancer and breast cancer SEQ ID NO: 5
- An antigen binding domain SEQ ID NO: 6 that binds to glypican1 overexpressed
- Another feature of the present invention is the additional introduction of three glycines between the antigen binding domain and the hinge region in order to increase the solubility of the CAR protein and increase the expression of the chimeric antigen receptor.
- the difference in solubility was about 10-fold when the three glycines were introduced between the antigen-binding domain and the hinge region, and thus, related to the preparation of CAR-T cells.
- the three glycine (K) may be substituted with alanine (A), valine (V), leucine (L) or isoleucine (I) amino acids of similar properties.
- Another feature of the invention lies in the use of certain secondary stimulatory domains.
- CAR-T cells the binding of the antigen binding domain to the antigen activates the T cell immune response via the cytoplasmic signal domain (CD3 ⁇ ).
- Auxiliary stimulation domain is a site where auxiliary stimulation signals are transmitted, and CAR-T cells that recognize a specific antigen bound to an antigen binding domain are responsible for transmitting an immune response, helping to proliferate, and increase the time remaining in the body. do.
- these co-stimulatory domains were components that did not exist in first-generation CAR-T cells, one co-stimulatory domain was used in second-generation CAR-T cells, and two co-stimulatory domains in third-generation CAR-T cells.
- CAR-T cells increase the self-proliferative capacity of CAR-T cells in the co-stimulatory domain and increase the time remaining in the body as the generations of the first, second, and third generations pass. Even after injecting the cell number, CAR-T cells are produced in the body against cancer cells, and they are recombined and developed into genes that can persist in the body even after injection. In other words, in the first generation, there was a limit of signal transmission because there was only CD3 ⁇ without the auxiliary stimulation signal domain, but in the second and third generations, 4-1BB or OX40 was introduced into the domain to improve cancer cell specific recognition ability. I wanted to.
- the present inventors used an auxiliary stimulating domain that mutated the CD28 at a predetermined position so that the therapeutic effect could be achieved even using fewer CAR-T cells.
- auxiliary stimulating domain that mutated the CD28 at a predetermined position so that the therapeutic effect could be achieved even using fewer CAR-T cells.
- the auxiliary stimulation domain comprises CD28 or TNFRSF9, or includes CD28 and TNFRSF9.
- CD28 may comprise a mutation (SEQ ID NOS: 6-9 substituting RRGH for RGGH) to increase expression of the chimeric antigen receptor.
- the amino acid sequences of the wild type CD28 and TNFRSF9 which may be included as auxiliary stimulatory domains of the present invention are represented by SEQ ID NOs: 7 and 8, respectively.
- the substituted amino acid is glycine (G), but similar amino acids such as alanine (A), valine (V), leucine ( L) or isoleucine (I).
- the hinge region of the present invention is a portion that connects the antigen binding domain and the transmembrane domain and is called a spacer, and has the purpose of extending the antigen binding domain from the T cell membrane.
- the hinge portion of the present invention may use a hinge region commonly used in the art, and may be derived from, for example, a CD8 hinge region (SEQ ID NO: 9, SEQ ID NO: 10). Another technical feature of the present invention is as described above, with three glycines further introduced between the antigen binding domain and the hinge region.
- the transmembrane domain of the present invention serves as a supporter of the CAR molecule and at the same time transmits the signal received from the antigen binding domain to the auxiliary stimulation domain and the cytoplasmic signal domain.
- Conventional transmembrane domains used for CAR production can be used without being limited to the transmembrane domain of the present invention, for example, human CD8 / CD3 transmembrane domains can be used (SEQ ID NO: 11, SEQ ID NO: 12).
- the cytoplasmic signal domain of the present invention used a normal human CD3 ⁇ signaling domain containing additional glutamine but not the CD3 ⁇ signaling domain of Jurkat T cells, wherein the additional glutamine is 50 in SEQ ID NO: 13 Glutamine at position Q.
- CAR-T cells comprising a predetermined antigen binding site disclosed in the present invention; CAR-T cells which further introduce three glycines between a given antigen binding domain and a given hinge region; It includes all CAR-T cells comprising the adjuvant stimulating domain disclosed herein.
- Nucleic acid sequences of polypeptides constituting the domains disclosed herein can be obtained using recombinant methods known in the art, for example, by screening libraries from cells expressing such genes using standard techniques, or And by inducing a gene from a vector known to contain the same gene, or by isolating directly from cells and tissues comprising the same gene.
- the gene of interest may be produced by synthesis, not cloning.
- Expression vectors can be rapidly introduced into host cells by any method known in the art.
- CAR-T cells can be prepared by conjugating the finally produced CAR gene fragment to MFG retrovirus expression vector digested with XhoI / NotI. It is to be understood that the present invention encompasses any number of variants for each of the components of the construct.
- Cancers that can be treated may include glioblastoma, as well as non-solid tumors (eg, hematologic tumors such as leukemia and lymphoma), or may include solid tumors.
- the genetically modified CAR-T cells are manufactured and injected into cancer patients. After extracting the T cells through the leukocyte component separation and collection process in the patient's blood, the DNA designed into the CAR is injected into the T cells using the expression vector, the CAR-T cells are expanded, and then injected into the patient.
- Example 1 Generation 2 (YYB-103, IL13.E11K.R64D.S67D.R107K.TNFRSF9.CD3 ⁇ ) and Generation 3 (YYB-103A, IL13.E11K.R64D) that specifically bind to IL13R ⁇ 2 overexpressed cancer cells .S67D.R107K.28.TNFRSF9.CD3 ⁇ ) Construction of expression vectors with chimeric antigen receptors
- IL13 E11K.R64D.S67D.R107K
- IL13 Glu-11, Arg-107
- cytoplasmic signal domain for T cell activation.
- Chimeric antigen receptors were constructed comprising one (TNFRSF9) and two (CD28, TNFRSF9) (FIG. 1).
- three glycines (GGG) were added between the antigen binding domain and the hinge to increase the solubility of the CAR protein and increase the expression of the chimeric antigen receptor (FIG. 2).
- the CD28 signal cytoplasmic domain used in the present invention comprises a mutant (RLLH ⁇ RGGH) human CD28 base sequence for increasing the solubility of the CAR protein to increase the expression of the chimeric antigen receptor (FIG. 3).
- CD3 zeta signaling domains of human TNFRSF9 and healthy humans were used.
- Human literature and public use of human IL13 (P35225.1), human CD3 (P20963-1), human CD8 ⁇ (P01732), human CD28 (P10747), human TNFRSF9 (Q07011), and human kappa light chain signal sequence (HuVHCAMP) Optimized using a possible database, 2nd and 3rd generation chimeric antigen receptors (YYB-103, IL13.E11K.R64D.S67D.R107K.TNFRSF9.CD3 ⁇ and YYB-103A, IL13.E11K.) Composed of codon-optimized synthetic DNA. R64D.S67D.R107K.28.TNFRSF9.CD3 ⁇ ) were produced (FIG. 1).
- the completed construct was composed of kozak consensus ribosome-binding sequence, human kappa light chain signal sequence (HuVHCAMP), human IL13.E11K.R64D.S67D.R107K mature protein sequence (human IL13 (E11K.R64D.S67D.R107K)), CAR protein Add three glycine (GGG) between the antigen binding domain and the hinge ( Figure 2), the hinge region of human CD8 ⁇ , the human CD8 / CD3 membrane transmembrane domain, mutation (RLLH ⁇ RGGH) to increase the solubility and increase the expression of the chimeric antigen receptor.
- HuVHCAMP human kappa light chain signal sequence
- Human IL13.E11K.R64D.S67D.R107K mature protein sequence human IL13 (E11K.R64D.S67D.R107K)
- CAR protein Add three glycine (GGG) between the antigen binding domain and the hinge ( Figure 2), the hinge region
- the entire sequence of YYB-103 and YYB-103A is shown in SEQ ID NOs: 14 and 15.
- the finally produced CAR gene fragment was conjugated to MFG retrovirus expression vector digested with XhoI / NotI (Emtage PC et al., Clin Cancer Res, 2008, 14: 8112-8122) (FIG. 1).
- High titer PG13 clones expressing CARs were temporarily infected with Phoenix-Empo and Phoenix-Eco cells using the retroviral expression vectors YYB-103 or YYB-103A constructed in Example 1, followed by infected Phoenix.
- Cell-free vector stocks from -empo and phoenix-echo cells were made by infecting PG13 cells.
- High titer monoclones were stained by anti-IL-13 monoclonal antibody (BD Pharmingen) and stained with PG13 / YYB-103 cells and then isolated by a flow cytometer.
- High titer PG13 / YYB-103 clones were made by second subcloning by limiting dilution.
- Subclonal PG13 / YYB-103-13 stably showed high CAR expression and was selected for efficient transduction ability in peripheral blood.
- PG13 / YYB-103-13 cells transduced with anti-IL-13 monoclonal antibody (BD Pharmingen) were analyzed for flow transduction using flow cytometry analysis.
- Supernatants of transduced PG13 / YYB-103-13 cells contain retroviruses and were harvested for genetic modification of T cells.
- Peripheral blood mononuclear cells (PBMC) were isolated by centrifugation into whole blood obtained from healthy donors in Ficoll Paque (GE Healthcare).
- T cell fractions were activated by incubating the isolated PBMCs with 100 ng / mL of anti-CD3 monoclonal antibody (eBioscience) in human IL-2 (NOVARTIS) at 100 IU / mL (BL Levine, Cancer Gene Therapy, 2015, 22: 79-84). After 2-3 days of incubation, most of the cells were T cells and some natural killer cells were present at 0% to 2%. After 2-3 days of activation, cells were propagated in flasks for 4-7 days after two transduction runs and washes over 2 days using retroviral supernatant to T cells. Cells were incubated on a platform device for agitation (WAVE bioreactor system) for 12-14 days. IL-2 was maintained at 100 IU / mL. T cells modified in this manner were used for the assay (FIG. 4).
- BD LSRII instrument Becton Dickinson
- BD FACSDiva software Becton Dickinson
- flow cytometry > 30,000 events. Specifically, cells were washed once in PBS containing 2% bovine serum albumin before adding PE-conjugated anti-human IL-13 monoclonal antibody (BD Pharmingen). After washing, the cells were reacted with each antibody for 30 minutes at 4 ° C in a light-blocked state, and then the cells were washed once and the expression rate of the transduced T cell surface CAR was checked.
- BD Pharmingen PE-conjugated anti-human IL-13 monoclonal antibody
- IL13R ⁇ 2 and IL13R ⁇ 1 were used to confirm cell surface expression of IL13R ⁇ 2 and IL13R ⁇ 1.
- anti-human IL13R ⁇ 2 antibody R & D systems
- donkey anti-goat IgG phycoerythrin secondary antibody R & D systems
- anti-human IL13R ⁇ 1 phycoerythrin R & D systems
- the isotype antibody was included as a control.
- IL13R ⁇ 2 specific CARs prepared in Example 1 (YYB-103, IL13.E11K.R107K.TNFRSF9.CD3 ⁇ ; YYB-103A, IL13.E11K.R64D.S67D.R107K.28.TNFRSF9.CD3 ⁇ ; YYB-103B, IL13
- T cell culture was carried out for 12-14 days according to Example 2, followed by flow cytometric analysis according to the experimental method. Proceeded.
- the expression rate of the chimeric antigen receptor expressed on the surface of living T cells was 90.5% to 92.8% in all 7 blood donors.
- expression of the IL13R ⁇ 2-specific chimeric antigen receptor remained stable up to 4 weeks without additional T cell activation or transduction.
- the ratio of total T cells, CD4 T cells, CD8 T cells, B cells, and Monocytes in the cultured cells was analyzed. As a result, it was confirmed that 0.5 ⁇ 1.2% was present in the B cells, but does not exist in the case of Monocyte.
- Example 3 Generation 2 (YYB-103, IL13.E11K.R64D.S67D.R107K.TNFRSF9.CD3 ⁇ ) and Generation 3 (YYB-103A, IL13.E11K.R64D) that specifically bind to IL13R ⁇ 2 overexpressed cancer cells S67D.R107K.28.TNFRSF9.CD3 ⁇ ) Measurement of cytotoxicity and IFN- ⁇ secretion of T cells transformed with chimeric antigen receptors
- the CAR-T cells prepared in Example 2 were used to measure IL13R ⁇ 2-specific cytotoxicity and secretion of IFN- ⁇ .
- Cytotoxicity assay was performed using DELFIA (Perkin Elmer) kit to measure the cytolytic activity of IL13R ⁇ 2-specific CAR-T cell effector (IL13R ⁇ 2-specific CAR + T cell effector). Specifically, CAR-T cell effector cells were used for 12-14 days after cell activation with anti-CD3, and the ratio of 5: 1 (effector: target) and 0.625: 1 (effector) in 96 well plates containing IL13R ⁇ 2 target cells. The effector cells were added at a ratio of: target), and the conditions of reacting for 2 hours at 37 ° C consisted of 3 repeated experiments. In the 96 well plate used in the assay, 5,000 target cells were added per well, and the target cells used were U251, a glioblastoma cell line overexpressing IL13R ⁇ 2, and primary HUVEC as a normal cell control.
- DELFIA Perkin Elmer
- IL13R ⁇ 2 specific CARs produced through the present invention (YYB-103, IL13.E11K.R64D.S67D.R107K.TNFRSF9.CD3 ⁇ ; YYB-103A, IL13.E11K.R64D.S67D.R107K.28.TNFRSF9.CD3 ⁇ ; YYB -103B, IL13.E11K.R107K.28.TNFRSF9.CD3 ⁇ ) T cells were analyzed to effectively kill target cancer cells (U251) overexpressing IL13R ⁇ 2.
- the above-described target cancer cells (U251) and normal cells (HUVEC) were cultured with each activated CAR-T cell, and a method of comparing the cytotoxicity was used.
- U251 and normal cells HuVEC
- FIG. 5 the expression of CAR-specific IL13R ⁇ 2 induced death of glioblastoma U251 cells expressing IL13R ⁇ 2 at a high level compared to activated T cells without transduction.
- YYB-103 (IL13.E11K.R64D.S67D.R107K.TNFRSF9.CD3 ⁇ ) and YYB-103A (IL13.E11K.R64D.S67D.R107K.28.TNFRSF9.CD3 ⁇ ) prepared in Example 2 of the present invention.
- YYB-103B (IL13.E11K.R107K.28.TNFRSF9.CD3 ⁇ ) for T cells expressing CAR, cytotoxicity gradually increased with increasing E: T ratio, but for T cells not expressing CAR There was little increase in toxicity.
- YYB-103B (IL13.E11K.R107K.28.TNFRSF9.CD3 ⁇ ) CAR substituted with two amino acids of IL13 and YYB substituted with four amino acids of IL13 used to impart higher antigen affinity.
- mutant IL13.E11K.R64D.S67D.R107K substituted with four amino acids of IL13 was compared with that of T-cells with mutant IL13.E11K.R107K substituted with two amino acids of IL13. It is shown to be superior to both 2nd Generation and 3rd Generation over cytotoxicity.
- IL13R ⁇ 2 is not expressed as a target for comparison with target cells
- IL13R ⁇ 1 is a very weak cytotoxicity for IL13R ⁇ 2 specific CAR-T cells (12.3 ⁇ 14% cytotoxicity) in experimental results using minimally expressed HUVEC cells as normal cell control. It was confirmed to have (Fig. 5).
- Fig. 5 shows that the chimeric antigen receptor used in the experiment specifically binds to IL13R ⁇ 2 due to the characteristics of HUVEC cells in which IL13R ⁇ 1 is expressed and IL13R ⁇ 2 is not expressed.
- This experimental example demonstrates that IL13R ⁇ 2-specific chimeric antigen receptor T cells are not toxic to normal cells (HUVEC) and can significantly kill target cancer cells (U251) expressing IL13R ⁇ 2.
- Cytotoxicity analysis was performed to measure the change of anticancer activity according to the expression rate of IL13R ⁇ 2-specific CAR. Specifically, 2nd Generation IL13.E11K.R64D.S67D.R107K.TNFSFR9.CD3 ⁇ , which is YYB-103, was used as CAR-T cells, and a U251 cell line overexpressing IL13R ⁇ 2 was used as a target cell. For cytotoxicity analysis, the ratio of effector cells to target cells was 0.625: 1 and 5: 1, and the ratio of T cells expressing CAR was 0 to 70%. Detailed method of the cytotoxicity assay is the same as the experimental method of Experimental Example 2.
- IL13R ⁇ 2-specific CARs In the absence of T cells expressing IL13R ⁇ 2-specific CARs, the cytotoxicity was 16.4% and 2.5% at 5: 1 and 0.625: 1 ratios, respectively. However, cytotoxicity increased as the proportion of T cells expressing IL13R ⁇ 2-specific CAR increased. When the ratio of T cells expressing IL13R ⁇ 2-specific CAR was 70%, the ratio was 5: 1 and 0.625: 1. It was confirmed that IL13R ⁇ 2-specific chimeric antigen receptor T cells can kill IL13R ⁇ 2-specific target cancer cells (U251) by showing cytotoxicity of 86% and 26%, respectively (FIG. 6).
- CAR-T cells specific for untransduced activated T cells and 10-70% of IL13R ⁇ 2 and untransduced to prepared 96 well tissue culture plates were prepared. It was added as an effector (0.5 ⁇ 10 ⁇ 5) and co-cultured with two replicate experiments.
- 7500 CAR-Ts were step-diluted with an effector, and co-cultured in a duplicated (duplicate) experiment. After 19 hours of incubation, the culture supernatant was used to conduct IFN- ⁇ assay experiments with ELISA analyzers (R & D systems) according to the analyzer manufacturer's instructions ( Figures 7, 8).
- activated T cells produce cytokines that help their growth and activity, and IFN- ⁇ is secreted by CD8 T cells, CD4 T cells, and NK cells. Plays an important role in the adaptive immune response. In particular, it plays an important role in not only inhibiting the occurrence of cancer but also causing T cells to migrate to the tumor site.
- This experimental example confirmed that the production of IFN- ⁇ was increased when T cells expressing IL13R ⁇ 2-specific CARs met the target cells.
- IL13R ⁇ 2-specific CAR-T cells were co-cultured with target cells (HUVEC cells, U251 cells), and then IFN- ⁇ was quantified by ELISA analysis.
- Figure 7 shows the increased IFN- ⁇ upon IL13R ⁇ 2 antigen binding according to the transduction ratio of the produced chimeric antigen receptor, it can be seen that the production pattern of IFN- ⁇ is different depending on the ratio of CAR-T cells.
- U251 a target cancer cell
- T cells without transduction of chimeric antigen receptor produced little IFN- ⁇ .
- the production of IFN- ⁇ was increased by 30%, and since it was no longer increased, 30% of CAR-T cells alone were sufficient to remove target cancer cells. Judging.
- FIG. 8 shows the IFN- ⁇ increased with the number of T cells having the chimeric antigen receptor produced, IFN- ⁇ increased as the number of cells in both YY6 and YY7 donors increased. This indicates that CAR-T cells are dependent on cell number in killing cancer cells.
- Example 4 In vivo efficacy evaluation using YYB-103
- Tumors were induced by subcutaneous injection of cancer cells into nude mice to evaluate whether YYB-103 actually showed efficacy in vivo, and confirmed the change of tumor size and the presence of CAR-T cells in the tumor site after YYB-103 treatment. It was.
- U251 cell line was injected subcutaneously into nude mice.
- control PBS and treatment group YYB-103 were administered once intravenously.
- Temozolomide (TMZ) and IL-2 were administered to the control and experimental groups for 4 days, once daily intraperitoneally and intravenously, respectively. Tumor size was measured at the start of treatment and 12 days after treatment, and necropsy was performed 15 days after treatment to determine tumor weight and histological analysis (FIG. 9).
- YYB-103 seems to be a less aggressive tumor due to the inhibition of angiogenesis in the tumor site (Fig. 11A, Fig. 11B).
- Example 5 Constructing a CAR capable of recognizing various solid tumors and neovascularization and preparing a PG13 producing cell line stably expressing the CAR
- Inhibiting angiogenesis which allows new blood vessels to grow into the tumor site, can inhibit the metastasis and growth of cancer cells.
- Successful anticancer CAR therapies require this approach because of the need for access of CAR-T cells to cancer cells as well as antigen-specific CAR-T cells and an immunosupportive environment for maintaining CAR-T cell function.
- An anti-angiogenic CAR was prepared for this (FIG. 12A).
- CARs targeting EGFRvlll, a major tumor antigen such as glioblastoma and lung cancer were constructed (FIG. 13A).
- EphA2 (Membrane-bound erythropoietin-producing hepatocellular receptor tyrosine kinase class A2) is overexpressed in breast cancer, prostate cancer, bladder cancer, skin cancer, lung cancer, ovarian cancer, and brain cancer, thereby producing a CAR targeting EphA2 (FIG. 14A). .
- Integrin alpha (V) beta (3) ( ⁇ V ⁇ 3) is highly expressed on tumor epithelial cells activated as glycoprotein membrane receptors.
- CARs targeting the tyrosine kinase (RTKIs) resistance markers such as carcinoma stemness and erlotinib of pancreatic cancer, lung cancer and breast cancer, were manufactured (FIG. 15A).
- GPC1 is important for efficient growth, metastasis, and angiogenesis of cancer cells, and GPC1 is overexpressed in pancreatic cancer, breast cancer, glioblastoma (FIG. 16A).
- BD LSRII instrument Becton Dickinson
- BD FACSDiva software Becton Dickinson
- flow cytometry > 30,000 events. Specifically, the cells were washed once in PBS containing 2% bovine serum albumin before the antibody was added. After washing, the cells were reacted with each antibody at 4 ° C. for 30 minutes in a light-blocked state, and then washed once and checked the expression rate of the transduced T cell surface CAR to detect the anti-human Fibronectin monoclonal antibody, PE-.
- the present invention relates to a rapidly developing CAR-T cell in the field of cancer treatment, which can be used in the medical industry in the field of customized cancer treatment.
- SEQ ID NO: 1 ⁇ Sequence of an antigen binding wild type IL-13 domain that binds IL13R ⁇ 2 ⁇
- SEQ ID NO: 2 Antigen binding domain capable of binding to an antigen associated with angiogenesis
- SEQ ID NO: 3 antigen binding domain that binds to EGFRvlll
- SEQ ID NO: 4 antigen binding domain that binds to EphA2
- SEQ ID NO: 13 CD3 ⁇ comprising additional glutamine ⁇
- SEQ ID NO: 16 ⁇ YYB-103B, IL13 (E11K.R107K). 28.TNFRSF9.CD3 ⁇
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (22)
- 항원 결합 도메인; 힌지 영역; 막통과 도메인; 보조 자극 도메인; 및 세포질 신호 도메인을 포함하는 키메라 항원 수용체에 있어서, 보조 자극 도메인이 돌연변이된 CD28 또는 TNFRSF9인 것을 특징으로 하는 키메라 항원 수용체.
- 제 1항에 있어서, 상기 돌연변이된 CD28은 서열번호 7번에 기재된 아미노산 서열의 6번 내지 9번 위치의 아미노산이 RLLH에서 RGGH 또는 RGGH와 유사한 성질의 아미노산으로 치환 된 것을 특징으로 하는 키메라 항원 수용체.
- 제 2항에 있어서, RGGH와 유사한 성질의 아미노산은, 글리신(G)이 알라닌(A), 발린(V), 류신(L) 또는 이소류신(I)으로 치환된 것을 특징으로 하는 키메라 항원 수용체.
- 제 1항 내지 제 3항 중 어느 한 항에 있어서, 보조 자극 도메인은 돌연변이된 CD28 및 TNFRSF9으로 이루어지는 것을 특징으로 하는 키메라 항원 수용체.
- 항원 결합 도메인; 힌지 영역; 막통과 도메인; 보조 자극 도메인; 및 세포질 신호 도메인을 포함하는 키메라 항원 수용체에 있어서, 항원 결합 도메인과 힌지 영역 수용체 사이에 추가로 3개의 글리신(G) 또는 글리신과 유사한 성질의 아미노산이 도입된 것을 특징으로 하는 키메라 항원 수용체.
- 제 5항에 있어서, 글리신과 유사한 성질의 아미노산은 알라닌(A), 발린(V), 류신(L) 또는 이소류신(I)인 것을 특징으로 하는 키메라 항원 수용체.
- 항원 결합 도메인; 힌지 영역; 막통과 도메인; 보조 자극 도메인; 및 세포질 신호 도메인을 포함하는 키메라 항원 수용체에 있어서, 항원 결합 도메인이 IL13Rα2, 혈관 신생 작용과 관련된 항원, EGFRvlll, EphA2, αVβ3, 및 glypican1으로 이루어지는 군으로부터 선택되는 항원과 결합하는 것을 특징으로 하는 키메라 항원 수용체.
- 제 7항에 있어서, 상기 항원 결합 도메인은 IL13Rα2와 결합하는 것을 특징으로 하는 키메라 항원 수용체.
- 제 8항에 있어서, 상기 항원 결합 도메인은 서열번호 1번으로 표시되는 아미노산 서열의 11번 위치가 리신으로 치환되고, 107번 위치가 리신으로 치환된 아미노산 서열을 갖는 것을 특징으로 하는 키메라 항원 수용체.
- 제 8항에 있어서, 상기 항원 결합 도메인은 서열번호 1번으로 표시되는 아미노산 서열의 11번, 64번, 67번 및 107번 위치가 각각 리신(K), 아스파르트산(D), 아스파르트산(D) 및 리신(K) 또는 이와 유사한 아미노산으로 치환된 것을 특징으로 하는 키메라 항원 수용체.
- 제 10항에 있어서, 이와 유사한 아미노산으로 치환된 것은, 11번에서는 리신(K) 대신에 아르기닌(R) 또는 히스티딘(H)로; 64번 및 67번에서는 아스파르트산(D) 대신에 글루탐산(E)으로; 107번에서는 리신(K) 대신에 히스티딘(H)으로 치환된 것을 특징으로 하는 키메라 항원 수용체.
- 항원 결합 도메인; 힌지 영역; 막통과 도메인; 보조 자극 도메인; 및 세포질 신호 도메인을 포함하는 키메라 항원 수용체에 있어서, 상기 세포질 신호 도메인이 추가의 글루타민(extra Glutamine)이 포함된 정상 인간(normal person)의 CD3ζ 신호전달 도메인인 것을 특징으로 하는 키메라 항원 수용체.
- 제 12항에 있어서, 상기 추가의 글루타민(extra Glutamine)은 정상 인간(normal person)의 CD3ζ 신호전달 도메인의 서열 50번째 위치에 존재하는 글루타민인 것을 특징으로 하는 키메라 항원 수용체.
- 제 13항에 있어서, 상기 CD3ζ 신호전달 도메인은 서열번호 13으로 표시되는 서열인 것을 특징으로 하는 카메라 항원 수용체.
- 제 1항에 있어서, 서열번호 14으로 표시되는 키메라 항원 수용체.
- 제 1항에 있어서, 서열번호 15으로 표시되는 키메라 항원 수용체.
- 제 1항, 제 5항, 제 7항, 제 10항, 제 12항 또는 제 16항 중 어느 한항에 따른 키메라 항원 수용체가 발현된 CAR-T 세포.
- 제 7항에 있어서, 서열번호 17 또는 서열번호 18로 표시되는 혈관 신생 작용과 관련된 항원과 결합하는 키메라 항원 수용체.
- 제 7항에 있어서, 서열번호 19 또는 서열번호 20으로 표시되는 EGFRvIII와 결합하는 키메라 항원 수용체.
- 제 7항에 있어서, 서열번호 21 또는 서열번호 22로 표시되는 EphA2와 결합하는 키메라 항원 수용체.
- 제 7항에 있어서, 서열번호 23 또는 서열번호 24로 표시되는 αVβ3와 결합하는 키메라 항원 수용체.
- 제 7항에 있어서, 서열번호 25 또는 서열번호 26으로 표시되는 글리피칸1(glypican1)과 결합하는 키메라 항원 수용체.
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2994797A CA2994797C (en) | 2015-08-05 | 2016-08-05 | Chimeric antigen receptors, and t cells in which chimeric antigen receptor is expressed |
EP19185670.7A EP3575403A1 (en) | 2015-08-05 | 2016-08-05 | Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed |
EP16833374.8A EP3333264B1 (en) | 2015-08-05 | 2016-08-05 | Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed |
KR1020177035539A KR102011789B1 (ko) | 2015-08-05 | 2016-08-05 | 키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포 |
AU2016301932A AU2016301932B2 (en) | 2015-08-05 | 2016-08-05 | Chimeric antigen receptor, and T cells in which chimeric antigen receptor is expressed |
RU2018107535A RU2724738C2 (ru) | 2015-08-05 | 2016-08-05 | Химерный антигенный рецептор и т-клетки, в которых экспрессируется химерный антигенный рецептор |
JP2018505599A JP6751493B2 (ja) | 2015-08-05 | 2016-08-05 | キメラ抗原受容体及びキメラ抗原受容体が発現されたt細胞 |
ES16833374T ES2877090T3 (es) | 2015-08-05 | 2016-08-05 | Receptor de antígenos quiméricos y células T en las que se expresa el receptor de antígenos quiméricos |
US15/750,453 US10975148B2 (en) | 2015-08-05 | 2016-08-05 | Chimeric antigen receptors, and T cells in which chimeric antigen receptor is expressed |
SG11201800872QA SG11201800872QA (en) | 2015-08-05 | 2016-08-05 | Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed |
CN201680045726.4A CN108026534B (zh) | 2015-08-05 | 2016-08-05 | 嵌合抗原受体和其中表达有嵌合抗原受体的t细胞 |
MX2018001502A MX2018001502A (es) | 2015-08-05 | 2016-08-05 | Receptor de antigeno quimerico y celulas t en las cuales se expresa el receptor de antigeno quimerico. |
IL257295A IL257295B (en) | 2015-08-05 | 2018-02-01 | Chimeric antigen receptors, and T cells in which expression of a chimeric antigen receptor is measured |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150110788 | 2015-08-05 | ||
KR10-2015-0110788 | 2015-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017023138A1 true WO2017023138A1 (ko) | 2017-02-09 |
Family
ID=57943361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/008632 WO2017023138A1 (ko) | 2015-08-05 | 2016-08-05 | 키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포 |
Country Status (13)
Country | Link |
---|---|
US (1) | US10975148B2 (ko) |
EP (2) | EP3575403A1 (ko) |
JP (1) | JP6751493B2 (ko) |
KR (1) | KR102011789B1 (ko) |
CN (1) | CN108026534B (ko) |
AU (1) | AU2016301932B2 (ko) |
CA (1) | CA2994797C (ko) |
ES (1) | ES2877090T3 (ko) |
IL (1) | IL257295B (ko) |
MX (1) | MX2018001502A (ko) |
RU (1) | RU2724738C2 (ko) |
SG (2) | SG11201800872QA (ko) |
WO (1) | WO2017023138A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020050667A1 (ko) | 2018-09-05 | 2020-03-12 | 공석경 | 고형암을 위한 키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230092787A1 (en) * | 2020-02-17 | 2023-03-23 | University Of Virginia Patent Foundation | Car t cells targeting the integrin alphav beta3 exhibit robust anti-tumor responses against gliomas and other solid tumor malignancies |
CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技(香港)有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
CN116178562A (zh) * | 2021-11-29 | 2023-05-30 | 四川大学华西医院 | 基于efna1构建的嵌合抗原受体免疫细胞制备及其应用 |
CN114573711A (zh) * | 2022-03-04 | 2022-06-03 | 陕西师范大学 | 一种TanCAR的构建及其应用 |
KR20230148435A (ko) * | 2022-04-14 | 2023-10-25 | 주식회사 셀랩메드 | 키메릭 항원 수용체 및 hgf 결합 억제 물질의 조합 요법 |
KR20230148433A (ko) | 2022-04-14 | 2023-10-25 | 주식회사 셀랩메드 | 키메릭 항원 수용체 및 hgf 중화항체의 조합 요법 |
WO2023220128A1 (en) * | 2022-05-10 | 2023-11-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Targeting myeloid-derived suppressor cells (mdscs) in bladder cancer to enhance efficacy of adoptive cell therapy (act) |
WO2024106941A1 (ko) * | 2022-11-15 | 2024-05-23 | 주식회사 셀랩메드 | B7-h3 키메라 항원 수용체 및 이의 용도 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140271582A1 (en) * | 2013-03-15 | 2014-09-18 | City Of Hope | Cd123-specific chimeric antigen receptor redirected t cells and methods of their use |
US20150139943A1 (en) * | 2013-10-17 | 2015-05-21 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996003883A1 (en) | 1994-08-02 | 1996-02-15 | The General Hospital Corporation | Cells bearing cd4 decoy receptors and related molecules and methods |
EP2331566B1 (en) * | 2008-08-26 | 2015-10-07 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
BR122021026169B1 (pt) * | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
CN102775500A (zh) * | 2012-08-03 | 2012-11-14 | 郑骏年 | 嵌合抗原受体iRGD-scFv(G250)-CD8-CD28-CD137-CD3ζ及其用途 |
AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
CA2901115A1 (en) * | 2013-02-15 | 2014-08-21 | The Regents Of The University Of California | Heterodimeric conditionally active chimeric antigen receptor and methods of use thereof |
EP3021853A1 (en) | 2013-07-18 | 2016-05-25 | Baylor College Of Medicine | Method of enhancing potency of immune cells |
WO2015063069A1 (en) * | 2013-10-28 | 2015-05-07 | Benjamin Felder | Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors |
CA2933707A1 (en) | 2013-12-20 | 2015-06-25 | Fred Hutchinson Cancer Research Center | Tagged chimeric effector molecules and receptors thereof |
US10077316B2 (en) * | 2013-12-27 | 2018-09-18 | National University Corporation, Kochi University | Esophageal cancer marker and use thereof |
IL308324A (en) * | 2014-09-19 | 2024-01-01 | Hope City | IL13RA2-targeted chimeric antigen receptor T cells |
MX2017007272A (es) * | 2014-12-02 | 2018-06-06 | Roger Williams Hospital | Metodos y composiciones para tratar cancer. |
-
2016
- 2016-08-05 ES ES16833374T patent/ES2877090T3/es active Active
- 2016-08-05 MX MX2018001502A patent/MX2018001502A/es unknown
- 2016-08-05 SG SG11201800872QA patent/SG11201800872QA/en unknown
- 2016-08-05 EP EP19185670.7A patent/EP3575403A1/en not_active Withdrawn
- 2016-08-05 EP EP16833374.8A patent/EP3333264B1/en active Active
- 2016-08-05 CA CA2994797A patent/CA2994797C/en active Active
- 2016-08-05 AU AU2016301932A patent/AU2016301932B2/en active Active
- 2016-08-05 CN CN201680045726.4A patent/CN108026534B/zh active Active
- 2016-08-05 US US15/750,453 patent/US10975148B2/en active Active
- 2016-08-05 WO PCT/KR2016/008632 patent/WO2017023138A1/ko active Application Filing
- 2016-08-05 KR KR1020177035539A patent/KR102011789B1/ko active IP Right Grant
- 2016-08-05 JP JP2018505599A patent/JP6751493B2/ja active Active
- 2016-08-05 RU RU2018107535A patent/RU2724738C2/ru active
- 2016-08-05 SG SG10201912734PA patent/SG10201912734PA/en unknown
-
2018
- 2018-02-01 IL IL257295A patent/IL257295B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140271582A1 (en) * | 2013-03-15 | 2014-09-18 | City Of Hope | Cd123-specific chimeric antigen receptor redirected t cells and methods of their use |
US20150139943A1 (en) * | 2013-10-17 | 2015-05-21 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
Non-Patent Citations (4)
Title |
---|
BROWN, CHRISTINE E. ET AL.: "Bioactivity and Safety of IL 13Ralpha2-redirected Chimeric Antigen Receptor CD 8+ T Cells in Patients with Recurrent Glioblastotroma", CLINICAL CANCER RESEARCH, vol. 21, no. 18, 9 June 2015 (2015-06-09), pages 4062 - 4072, XP055362794 * |
JOHNSON, LAURA A. ET AL.: "Rational Development and Characterization of Humanized Anti-EGFR Variant III Chimeric Antigen Receptor T Cells for Glioblastoma", SCIENCE TRANSLATIONAL MEDICINE, vol. 7, no. 275, 18 February 2015 (2015-02-18), pages 1 - 14, XP055362795 * |
KOWOLIK, CLAUDIA M. ET AL.: "CD 28 Costimulation Provided Through a CD 19-specific Chimeric Antigen Receptor Enhances in Vivo Persistence and Antitumor Efficacy of Adoptively Transferred T Cells", CANCER RESEARCH, vol. 66, no. 22, 15 November 2006 (2006-11-15), pages 10995 - 11004, XP055044266 * |
See also references of EP3333264A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020050667A1 (ko) | 2018-09-05 | 2020-03-12 | 공석경 | 고형암을 위한 키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포 |
Also Published As
Publication number | Publication date |
---|---|
KR20170142995A (ko) | 2017-12-28 |
MX2018001502A (es) | 2018-08-01 |
EP3575403A1 (en) | 2019-12-04 |
JP6751493B2 (ja) | 2020-09-09 |
IL257295B (en) | 2022-05-01 |
JP2018522904A (ja) | 2018-08-16 |
CN108026534A (zh) | 2018-05-11 |
KR102011789B1 (ko) | 2019-08-19 |
SG10201912734PA (en) | 2020-02-27 |
CA2994797C (en) | 2021-07-20 |
CA2994797A1 (en) | 2017-02-09 |
EP3333264A4 (en) | 2019-01-02 |
US20180265585A1 (en) | 2018-09-20 |
AU2016301932B2 (en) | 2020-02-27 |
US10975148B2 (en) | 2021-04-13 |
SG11201800872QA (en) | 2018-03-28 |
CN108026534B (zh) | 2021-08-31 |
RU2018107535A3 (ko) | 2019-09-05 |
AU2016301932A1 (en) | 2018-03-01 |
RU2018107535A (ru) | 2019-09-05 |
EP3333264A1 (en) | 2018-06-13 |
ES2877090T3 (es) | 2021-11-16 |
EP3333264B1 (en) | 2021-03-31 |
RU2724738C2 (ru) | 2020-06-25 |
IL257295A (en) | 2018-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017023138A1 (ko) | 키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포 | |
WO2018124766A2 (ko) | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 | |
WO2020060122A1 (ko) | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도 | |
WO2018030806A1 (ko) | 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물 | |
WO2019182425A1 (ko) | 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도 | |
WO2021235696A1 (ko) | Cd22에 특이적인 항체 및 이의 용도 | |
WO2020153605A1 (ko) | 메소텔린 특이적인 키메라 항원 수용체 및 이를 발현하는 t 세포 | |
WO2017030370A1 (ko) | 항-코티닌 항체가 연결된 키메라 항체 수용체 및 이의 용도 | |
WO2011142514A1 (ko) | Pias3을 유효성분으로 포함하는 암 또는 면역질환의 예방 또는 치료용 조성물 | |
WO2021107689A1 (ko) | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 면역관문 억제제를 포함하는 암 치료용 약학 조성물 | |
WO2023277361A1 (ko) | 메소텔린 특이적 항체 및 이의 용도 | |
WO2011115456A2 (ko) | 자가 면역 질환 예방 및 치료용 TNF-α와 TWEAK 이중 길항제 | |
WO2011052883A2 (ko) | Socs2 유전자의 발현을 조절하여 자연 살해 세포를 활성화시키는 방법 | |
WO2022025638A1 (ko) | 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포 | |
WO2021153979A1 (ko) | 항-taa 항체, 항-pd-l1 항체 및 il-2를 포함하는 융합단백질 및 이의 용도 | |
WO2022145739A1 (en) | Humanized antibody specific for cd22 and chimeric antigen receptor using the same | |
WO2021162394A1 (ko) | B세포 성숙화 항원을 표적으로 하는 키메라 항원 수용체 및 이의 용도 | |
WO2022035200A1 (ko) | Il-12 및 항-cd20 항체를 포함하는 융합단백질 및 이의 용도 | |
WO2021235697A1 (ko) | Cd22에 특이적인 항체 및 이의 용도 | |
WO2021107635A1 (ko) | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 nk 세포를 포함하는 항암 치료용 조성물 | |
WO2018026249A1 (ko) | 프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도 | |
WO2020204305A1 (ko) | 항-메소텔린 항체, 항-cd3 항체 또는 항-egfr 항체를 포함하는 융합 단백질 및 이를 포함하는 이중 특이적 또는 삼중 특이적 항체 및 이의 용도 | |
WO2021246637A1 (ko) | Cd22에 특이적인 항체 및 이의 용도 | |
WO2022124765A1 (ko) | Gpc3에 특이적인 항체 및 이의 용도 | |
WO2021066612A2 (ko) | 종양 표적화 단백질 또는 이의 단편 및 그것에 결합하는 항체 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16833374 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20177035539 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018505599 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11201800872Q Country of ref document: SG Ref document number: MX/A/2018/001502 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2994797 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15750453 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2016301932 Country of ref document: AU Date of ref document: 20160805 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016833374 Country of ref document: EP Ref document number: 2018107535 Country of ref document: RU |